CIK 0001936258 · Large accelerated filer
NewAmsterdam Pharma Co N.V.
Sign in to watch- Ticker
- NAMS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Netherlands
- Entity type
- operating
- Phone
- 35 206 2971
- Business address
- GOOIMEER 2-35, NARRDEN, Netherlands, 1411 DC
- Former names
- NewAmsterdam Pharma Co B.V.
Securities
- NAMS Ordinary Shares Nasdaq
- NAMSW Warrant Nasdaq
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 4 Open-market sale Chief Executive Officer sold 443,707 shares at $33.25 ($14,753,258)
- 144 Insider Sale of Securities
- 8-K Event Regulation FD disclosure
- 4 Planned sale Chief Executive Officer sold 306,293 shares at an average $34.53 ($10,575,091)
- 4 Open-market sale Chief Scientific Officer sold 45,481 shares at an average $35.31 ($1,605,998)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- S-8 Other Securities Offered to Employees in Benefit Plans
- 10-K Report Annual Report
- 8-K Event Results of operations
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- 4 Planned sale Chief Accounting Officer sold 72,428 shares at an average $32.25 ($2,335,860)
- 4 Planned sale Chief Accounting Officer sold 72,572 shares at an average $33.29 ($2,415,843)
- 4 Planned sale Chief Financial Officer sold 100,000 shares at an average $32.61 ($3,260,618)
- 144 Insider Sale of Securities
- 4 Grant or award Director acquired 3,400 shares (grant or award)
- 4 Grant or award Director acquired 3,400 shares (grant or award)
Page 3 of 21 · 415 filings